Anand Rathi: Domestic Pharma Market Consolidates In July, Chronic Therapies Continue To Outshine
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
After entering positive territory in June, the Indian Pharmaceutical Market consolidated in July 2020.
Monthly sales at Rs 121 billion were flat YoY. The growth trend in chronic outpacing acute therapies continued for yet another month, and cardio (up 13%) has now surpassed anti-infectives (down 10%) to become the largest therapy in IPM.
Industry volumes declined 7%, while the prices rose 5%; launches aided 2% growth.
Listed pharma companies which did well in June are Glenmark Pharmaceuticals Ltd. (30%, due to a strong upswing in new Fabiflu), JB Chemicals and Pharmaceuticals Ltd. (13%) and Ipca Laboratories Ltd. (12%); sales of Wockhardt (brands divested to Dr. Reddy’s Laboratories Ltd.), Natco Pharma Ltd., GlaxoSmithKline Pharmaceuticals Ltd. and Indoco Remedies Ltd. continued to decline even in July.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.